[A15-31] Tiotropium/olodaterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Last updated 16.11.2015

Project no.:
A15-31

Commission:
Commission awarded on 13.08.2015 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Airways and respiratory system

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

16.11.2015

Tiotropium/olodaterol in COPD: disadvantages in patients with more severe disease, advantages for some women

More exacerbations in people with higher COPD severity grades / fewer symptoms in women with rare flare-ups

Project no. Title Status
A15-57 Tiotropium/olodaterol - Addendum to Commission A15-31 Commission completed

Federal Joint Committee (G-BA)

2016-02-04 G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.